Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Other financing activities (2021 - 2025)

Akebia Therapeutics (AKBA) has disclosed Other financing activities for 4 consecutive years, with $63000.0 as the latest value for Q1 2025.

  • On a quarterly basis, Other financing activities fell 91.6% to $63000.0 in Q1 2025 year-over-year; TTM through Dec 2025 was $63000.0, a 95.05% decrease, with the full-year FY2025 number at $63000.0, down 95.05% from a year prior.
  • Other financing activities was $63000.0 for Q1 2025 at Akebia Therapeutics, down from $522000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $44.8 million in Q1 2021 to a low of -$44.8 million in Q2 2021.
  • A 4-year average of $12.3 million and a median of $750000.0 in 2024 define the central range for Other financing activities.
  • Peak YoY movement for Other financing activities: decreased 10.68% in 2022, then plummeted 91.6% in 2025.
  • Akebia Therapeutics' Other financing activities stood at $44.8 million in 2021, then fell by 10.68% to $40.0 million in 2022, then plummeted by 98.7% to $522000.0 in 2024, then crashed by 87.93% to $63000.0 in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Other financing activities are $63000.0 (Q1 2025), $522000.0 (Q3 2024), and $750000.0 (Q1 2024).